Insights from the BioInfect Conference: Tackling Antimicrobial Resistance with Innovation and Collaboration
Antimicrobial Resistance (AMR) remains one of the biggest global health threats, and the recent BioInfect Conference shed light on the latest advancements and challenges in the fight against drug-resistant infections. With a strong presence of industry leaders, researchers, and biotech innovators, the conference emphasized the urgency of shifting towards precision medicine, fostering collaboration, and securing sustainable funding for AMR solutions.
AMR’s financial burden is often underestimated, making it difficult to secure the necessary funding for research and drug development. One compelling suggestion from the conference was to officially list AMR as a cause of death, on death certificates. This would highlight the true impact of AMR and drive policy changes and investment in solutions.
Scientific innovations pushing AMR research forward
- Organic chemistry techniques to identify drugs similar to natural antibiotics, reimagined by chemists.
- Inorganic chemistry approaches, such as creating heavy metal chelates and using inorganic compounds to generate immune responses against AMR.
- 2D models for non-clinical testing of antimicrobial drugs, such as developing a 'skin-on-a-chip' to replicate human skin physiology for drug testing.
Challenges in AMR Biotech and development
A recurring theme at BioInfect was the critical role of industry-academic collaborations in de-risking research and maximizing resources. Encouraging transparency, data sharing, and even publishing negative results can prevent redundant research efforts and drive more meaningful progress.
- Lloyd Payne underscored the importance of surrounding oneself with experienced professionals and leveraging expert advisory services.
- Erin Duffy (CARB-X) highlighted the need for strong clinical and regulatory strategies to attract investors and drive innovation forward.
The importance of non-dilutive funding
We’re committed to helping biotech companies navigate the complexities of AMR research and drug development. Our expertise includes:
- Grant writing: We collaborate with scientists to craft compelling, high-quality grant applications that secure funding
- Target product profiles & clinical development plans: Our team assists in designing protocol synopses and full protocols to align with clinical and regulatory strategies
- Clinical study reports: We handle everything from study report writing to publishing in top-tier scientific journals
- AMR & infectious disease expertise: Our medical writers have deep industry knowledge and a passion for combating infectious diseases, helping biotech innovators make a lasting impact